Vree T B, Van den Biggelaar-Martea M, Van Ewijk-Beneken Kolmer E W, Hekster Y A
Department of Clinical Pharmacy, Sint Radboud Hospital, University of Nijmegen, The Netherlands.
Pharm World Sci. 1993 Aug 20;15(4):165-70. doi: 10.1007/BF01880560.
The aim of this pilot study was to demonstrate the possible inhibitory effect of probenecid on the renal glucuronidation and on the renal clearance of nalidixic acid in a human volunteer. Under acidic urine conditions, hardly any nalidixic acid is excreted unchanged (0.2%). It is excreted as acyl glucuronide (53.4%), 7-hydroxymethylnalidixic acid (10.0%), the latter's acyl glucuronide 30.9%, and 7-carboxynalidixic acid (4.2%). Under probenecid co-medication the renal glucuronidation of nalidixic acid is reduced from 53% to 16%; the renal clearance of both nalidixic acid and 7-hydroxymethylnalidixic acid are reduced (p < 0.001); the intrinsic t1/2 of the metabolite 7-hydroxymethylnalidixic acid increased from 0.48 h to 4.24 h. The amount of acyl glucuronidation of 7-hydroxymethylnalidixic acid was not altered. The in vitro protein binding of both acyl glucuronides was increased, while no effect on the unconjugated compounds was seen. Nalidixic acid had no effect on the maximal renal excretion rate of probenecid acyl glucuronide.
这项初步研究的目的是在一名人类志愿者身上证明丙磺舒对萘啶酸的肾脏葡萄糖醛酸化及肾脏清除率可能存在的抑制作用。在酸性尿液条件下,几乎没有未变化的萘啶酸排出(0.2%)。它以酰基葡萄糖醛酸苷(53.4%)、7-羟甲基萘啶酸(10.0%)、后者的酰基葡萄糖醛酸苷(30.9%)以及7-羧基萘啶酸(4.2%)的形式排出。在同时服用丙磺舒的情况下,萘啶酸的肾脏葡萄糖醛酸化从53%降至16%;萘啶酸和7-羟甲基萘啶酸的肾脏清除率均降低(p < 0.001);代谢物7-羟甲基萘啶酸的固有半衰期从0.48小时增至4.24小时。7-羟甲基萘啶酸的酰基葡萄糖醛酸化量未改变。两种酰基葡萄糖醛酸苷的体外蛋白结合增加,而对未结合化合物未见影响。萘啶酸对丙磺舒酰基葡萄糖醛酸苷的最大肾脏排泄率无影响。